# A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

> **NCT02356562** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 29 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir and dasabuvir
- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02356562
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-03
- **Primary completion:** 2016-10-28
- **Final completion:** 2017-07-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02356562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02356562, "A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02356562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*